InVivo Therapeutics Holdings Corporation (NVIVQ) Research

InVivo Therapeutics Holdings Corp. is a U.S.-based biotechnology and biomaterials company, engaged in both research and clinical development. The company's primary focus is on pioneering and commercializing biopolymer scaffolding devices specifically designed for the treatment of spinal cord injuries (SCI). Its flagship product under development is the Neuro-Spinal Scaffold implant, which is constructed from a blend of biocompatible and bioresorbable polymers. These polymers include Poly lactic-co-glycolic acid (PLGA), a material frequently found in dissolvable sutures that provides crucial biocompatible support for the scaffold, and Poly-L-Lysine, a positively charged polymer used to encourage cellular attachment. Founded in 2003, InVivo Therapeutics maintains its headquarters in Cambridge, Massachusetts.

Market snapshot

Symbol
NVIVQ
Price
$0.37
Day change
+12.12%
Market cap
$1.1M
52-week range
0.15-1.41
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Digipath, Inc. (DIGP)
  • Evolva Holding S.A. (ELVAY)
  • Entourage Health Corp. (ETRGF)
  • Novation Companies, Inc. (NOVC)
  • Nutroganics, Inc. (NUTTQ)
  • Point of Care Nano-Technology, Inc. (PCNT)
  • RegenETP, Inc. (RGTPQ)

Open InVivo Therapeutics Holdings Corporation (NVIVQ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.